Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Net Income (2018 - 2025)

Historic Net Income for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$29.8 million.

  • X4 Pharmaceuticals' Net Income rose 1875.14% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$95.1 million, marking a year-over-year decrease of 46742.65%. This contributed to the annual value of -$37.4 million for FY2024, which is 6298.2% up from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Net Income is -$29.8 million, which was up 1875.14% from -$25.7 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Net Income high stood at $90.8 million for Q2 2024, and its period low was -$55.7 million during Q2 2023.
  • For the 5-year period, X4 Pharmaceuticals' Net Income averaged around -$19.8 million, with its median value being -$22.0 million (2022).
  • Data for X4 Pharmaceuticals' Net Income shows a peak YoY increase of 26304.03% (in 2024) and a maximum YoY decrease of 149201.74% (in 2024) over the last 5 years.
  • X4 Pharmaceuticals' Net Income (Quarter) stood at -$30.2 million in 2021, then rose by 3.65% to -$29.1 million in 2022, then surged by 34.27% to -$19.1 million in 2023, then crashed by 108.16% to -$39.8 million in 2024, then increased by 25.13% to -$29.8 million in 2025.
  • Its Net Income stands at -$29.8 million for Q3 2025, versus -$25.7 million for Q2 2025 and $282000.0 for Q1 2025.